Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6878-6887

  Hardy, Nancy M ^a   Mossoba, Miriam E ^a   Steinberg, Seth M ^a   Fellowes, Vicki ^a   Yan, Xiao Yi ^a   Hakim, Frances T ^a   Babb, Rebecca R ^a   Avila, Daniele ^a   Gea Banacloche, Juan ^a   Sportés, Claude ^a   Levine, Bruce L ^c   June, Carl H ^b   Khuu, Hahn M ^b   Carpenter, Ashley E ^a   Krumlauf, Michael C ^a   Dwyer, Andrew J ^b   Gress, Ronald E ^a   Fowler, Daniel H ^a   Bishop, Michael R ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIBODY; CD28 ANTIBODY; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GAMMA INTERFERON; GRANZYME; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MESNA; PERFORIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; STEROID; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE TRANSFER; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CAUSE OF DEATH; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DONOR; ENGRAFTMENT SYNDROME; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LYMPHOCYTE ACTIVATION; METASTASIS; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCED INTENSITY CONDITIONING; SEPSIS; SIBLING; T CELL DEPLETION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; BREAST NEOPLASMS; FEMALE; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MIDDLE AGED; NEOPLASM METASTASIS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 80455162303     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1579     Document Type: Article

References (41)

1. Gennari A. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Breast Dis A Year Book Quart 2008;19:180.
2. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13:98-107.
3. Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G, et al. Optimizing tumor-reactive gammadelta T cells for antibody-based cancer immunotherapy. Curr Mol Med 2010;10:719-26.
4. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004;22:3886-92. (Pubitemid 41079869)
5. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996;88:1501-8. (Pubitemid 26276829)
6. Or R, Ackerstein A, Nagler A, Kapelushnik J, Naparstek E, Samuel S, et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol Ther 1998;4:1-6. (Pubitemid 28192910)
7. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poorrisk patients with metastatic breast cancer. J Clin Oncol 1998;16:986-93. (Pubitemid 28108731)
8. Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 2004;126:837-43. (Pubitemid 39273825)
9. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005;366:318-20. (Pubitemid 41019423)
10. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008;41:537-45. (Pubitemid 351472145)
11. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, et al. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 2009;44:81-7.
12. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-14.
13. Champlin RE. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treat Res 1990;50:99-111.
14. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987;2:175-8. (Pubitemid 17091848)
15. Baron F, Beguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:351-9.
16. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000;38:221-34. (Pubitemid 30303657)
17. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994;84:3540-9. (Pubitemid 24352920)
18. + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J Immunol 1996;157:4811-21.
19. +, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 1996;2:118-25.
20. + T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection. Vox Sang 1998;74 Suppl 2:331-40.
21. Fuzak J, Jung US, Foley J, Eckhaus MA, Fowler DH. Allospecific Tc2 cells mediate a graft-vs.-tumor effect without inducing ongoing GVHD in a murine model of metastatic breast cancer. Blood 2000;96:2367.
22. Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH. CD3/CD28- costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 2003;102:3439-46. (Pubitemid 37314787)
23. Porter DL, Levine BL, Bunin N, Stadtmauer EA, LugerSM, Goldstein S, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325-31. (Pubitemid 43242365)
24. + T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:1150-60.
25. Fowler D, Hou J, Foley J, Hakim F, Odom J, Castro K, et al. Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant. Cytotherapy 2002;4:429-30. (Pubitemid 35375302)
26. Hardy NM, Fowler DH, Bishop MR. Immunotherapy of metastatic breast cancer: phase I trial of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange. Clin Breast Cancer 2006;7:87-9. (Pubitemid 43862841)
27. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P,Hows J, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
28. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989;4:247-54. (Pubitemid 19152518)
29. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood MarrowTransplant 2005;11:945-56. (Pubitemid 41754712)
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, et al. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:1022-30. (Pubitemid 47215557)
32. Spencer LA, Weller PF. Eosinophils and Th2 immunity: contemporary insights. Immunol Cell Biol 2010;88:250-6.
33. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178:4222-9. (Pubitemid 46492372)
34. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147-74.
35. + T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-48.
36. + regulatory T cell function by calcineurin dependent interleukin-2 production. Blood 2006;108:390-9.
37. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004;104:2187-93. (Pubitemid 39297878)
38. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-77. (Pubitemid 38496245)
39. Mariotti J, Foley J, Jung U, Borenstein T, Kantardzic N, Han S, et al. Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol 2008;180:89-105.
40. Foley JE, Jung U, Miera A, Borenstein T, Mariotti J, Eckhaus M, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 2005;175:5732-43. (Pubitemid 41508056)
41. Jung U, Foley JE, Erdmann AA, Toda Y, Borenstein T, Mariotti J, et al. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. Biol Blood Marrow Transplant 2006;12:905-18.